Copeland Capital Management LLC grew its holdings in Quest Diagnostics Incorporated (NYSE:DGX) by 5.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 164,331 shares of the medical research company’s stock after purchasing an additional 8,742 shares during the period. Copeland Capital Management LLC owned about 0.12% of Quest Diagnostics worth $15,388,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in DGX. Teachers Advisors LLC increased its stake in Quest Diagnostics by 23.6% in the first quarter. Teachers Advisors LLC now owns 219,065 shares of the medical research company’s stock worth $21,510,000 after purchasing an additional 41,822 shares during the period. Thrivent Financial For Lutherans grew its position in shares of Quest Diagnostics by 4.5% during the 1st quarter. Thrivent Financial For Lutherans now owns 5,100 shares of the medical research company’s stock worth $501,000 after buying an additional 220 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Quest Diagnostics during the 1st quarter worth $741,000. BlueCrest Capital Management Ltd bought a new position in shares of Quest Diagnostics during the 1st quarter worth $216,000. Finally, Paloma Partners Management Co bought a new position in shares of Quest Diagnostics during the 1st quarter worth $1,417,000. Institutional investors and hedge funds own 88.64% of the company’s stock.

DGX has been the topic of a number of recent research reports. Raymond James Financial, Inc. reissued a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, September 25th. Canaccord Genuity reissued a “buy” rating and set a $118.00 price target on shares of Quest Diagnostics in a research report on Wednesday, September 13th. ValuEngine raised Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Goldman Sachs Group, Inc. (The) downgraded Quest Diagnostics from a “conviction-buy” rating to a “buy” rating and dropped their price target for the stock from $121.00 to $113.00 in a research report on Tuesday, October 10th. Finally, Craig Hallum reissued a “hold” rating and set a $100.00 price target (down previously from $110.00) on shares of Quest Diagnostics in a research report on Tuesday, October 17th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $106.18.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://theolympiareport.com/2017/10/31/quest-diagnostics-incorporated-dgx-holdings-increased-by-copeland-capital-management-llc.html.

In other news, Chairman Stephen H. Rusckowski sold 2,525 shares of Quest Diagnostics stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $108.03, for a total transaction of $272,775.75. Following the sale, the chairman now directly owns 168,413 shares of the company’s stock, valued at $18,193,656.39. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey M. Leiden sold 296 shares of Quest Diagnostics stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $106.66, for a total value of $31,571.36. Following the sale, the director now directly owns 6,000 shares in the company, valued at $639,960. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 160,692 shares of company stock worth $17,375,423. Corporate insiders own 1.75% of the company’s stock.

Shares of Quest Diagnostics Incorporated (NYSE:DGX) traded down 0.31% on Tuesday, reaching $93.49. The company had a trading volume of 547,393 shares. Quest Diagnostics Incorporated has a 52 week low of $79.12 and a 52 week high of $112.96. The firm has a market capitalization of $12.75 billion, a P/E ratio of 18.84 and a beta of 0.66. The company’s 50-day moving average price is $96.26 and its 200 day moving average price is $104.50.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.92 billion. During the same period in the previous year, the company earned $1.37 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. On average, analysts expect that Quest Diagnostics Incorporated will post $5.64 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 18th. Stockholders of record on Tuesday, October 3rd were given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date of this dividend was Monday, October 2nd. Quest Diagnostics’s payout ratio is 37.74%.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.